SCHEMBL22470138

SCHEMBL22470138

O=C(O)N1CCOC[C@H]1CNC1(c2ccc(F)c(C(F)(F)F)c2)CC1

nearest known ligand 0.40

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 3/20 0.40
HCRTR1 O43613 10/20 0.37
HCRTR2 O43614 10/20 0.37
CYP3A4 P08684 7/20 0.37
NOTUM Q6P988 1/20 0.36
MCHR1 Q99705 1/20 0.35
RORC P51449 1/20 0.34
AKT1 P31749 1/20 0.34
P2RX7 Q99572 1/20 0.33
HDAC3 O15379 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22470078 1.00 KCNN4 (0.40) KCNN4HCRTR1HCRTR2CYP3A4NOTUM
SCHEMBL22470080 1.00 KCNN4 (0.40) KCNN4HCRTR1HCRTR2CYP3A4NOTUM
SCHEMBL29261962 0.87 IL1B (0.42) KCNN4HCRTR1HCRTR2CYP3A4MCHR1
SCHEMBL29261963 0.87 IL1B (0.42) KCNN4HCRTR1HCRTR2CYP3A4MCHR1
SCHEMBL29355246 0.87 IL1B (0.42) KCNN4HCRTR1HCRTR2CYP3A4MCHR1
SCHEMBL22470251 0.87 KCNN4 (0.44) KCNN4NOTUMMCHR1P2RX7HDAC3
SCHEMBL22470247 0.87 KCNN4 (0.44) KCNN4NOTUMMCHR1P2RX7HDAC3
SCHEMBL22470069 0.85 KCNN4 (0.49) KCNN4NOTUMMCHR1
SCHEMBL22470141 0.85 KCNN4 (0.49) KCNN4NOTUMMCHR1
SCHEMBL22470134 0.85 KCNN4 (0.49) KCNN4NOTUMMCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12006289-B2 Potassium channel inhibitors SANIONA A/S (DK) 2024-06-11 US disclosed
CN-113631538-B Novel potassium channel inhibitors 萨尼奥纳有限责任公司 2024-05-31 CN disclosed
US-20220169602-A1 NOVEL POTASSIUM CHANNEL INHIBITORS SANIONA A/S (DK) 2022-06-02 US disclosed
EP-3941903-A1 NOVEL POTASSIUM CHANNEL INHIBITORS Saniona A/S (DK) 2022-01-26 EP disclosed
CN-113631538-A Novel potassium channel inhibitors 萨尼奥纳有限责任公司 2021-11-09 CN disclosed
WO-2020193419-A1 NOVEL POTASSIUM CHANNEL INHIBITORS SANIONA A/S (DK) 2020-10-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220169602-A1 NOVEL POTASSIUM CHANNEL INHIBITORS KCNN2, KCNJ2, KCNN1 KCNN4 57/4885HCRTR1 2394/4885HCRTR2 1563/4885
US-12006289-B2 Potassium channel inhibitors KCNJ2, KCNN2, KCNN1 KCNN4 48/4885HCRTR1 2653/4885HCRTR2 1582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.